tenofovir has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brousseau, N; Gilca, V; Larouche, J; Mandal, S; Murphy, DG; Tedder, RS | 1 |
| Lampertico, P; Mangia, G; Viganò, M | 1 |
| Adamidi, S; Alexopoulou, A; Deutsch, M; Koskinas, JS; Manolakopoulos, S; Pectasides, D; Skondra, M; Tampaki, M | 1 |
| Arcaini, L; Gotti, M; Merli, M; Rattotti, S | 1 |
| Belvisi, V; Cenfra, N; Cimino, G; Del Borgo, C; Lichtner, M; Marocco, R; Mastroianni, CM; Mecarocci, S; Rago, A | 1 |
2 review(s) available for tenofovir and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Topics: Adenine; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Carrier State; Disease Management; DNA, Viral; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Organophosphonates; Rituximab; Tenofovir; Virus Activation | 2014 |
Antiviral therapies for managing viral hepatitis in lymphoma patients.
Topics: Antiviral Agents; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis C; Humans; Lamivudine; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Rituximab; Tenofovir; Virus Activation | 2017 |
3 other study(ies) available for tenofovir and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Acute hepatitis B virus infection with delayed appearance of hepatitis B core antibody in an immunocompromised patient: a case report.
Topics: Antiviral Agents; Contact Tracing; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Humans; Immunocompromised Host; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Middle Aged; Rituximab; Tenofovir; Treatment Outcome | 2017 |
The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Female; Hepatitis B; Humans; Immunocompromised Host; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organophosphonates; Rituximab; Tenofovir; Virus Activation | 2014 |
Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Drug Combinations; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Organophosphonates; Rituximab; Tenofovir; Virus Activation | 2010 |